12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGN1703: Interim Phase II data

Mologen reported that an initial assessment of data from 55 evaluable patients with mCRC in the double-blind, international Phase II IMPACT trial showed that twice-weekly 60 mg MGN1703 as maintenance therapy met the primary endpoint of median PFS vs. placebo. Specifically, median PFS in an undisclosed pre-defined target population of 46 patients showed that MGN1703 more...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >